We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 44.64 | 71 | 09:16:48 |
From Apr 2019 to Apr 2024
By Dave Sebastian
Shares of Bristol-Myers Squibb Co. (BMY) rose more than 5% in premarket trading after Amgen Inc. (AMGN) on Monday said it agreed to buy Celgene Corp.'s (CELG) psoriasis treatment Otezla, paving the way for Bristol-Myers to acquire Celgene.
The deal is worth about $13.4 billion in cash, Amgen said.
In January, Bristol-Myers said it would acquire Celgene at about $74 billion, but the U.S. Federal Trade Commission raised anticompetitive concerns related to anti-inflammatory drugs. The companies in June said they would shed Otezla to satisfy the FTC's concerns.
Shares of Celgene rose more 3.2% in premarket trading, while Amgen shares declined more than 1%.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
August 26, 2019 07:59 ET (11:59 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
